Pfizer CEO Dr. Albert Bourla and chair of the PhRMA Board of Directors Pharmaceutical Research and Manufacturers of America (PhRMA) Pfizer CEO Dr. Albert Bourla and chair of the PhRMA Board of ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already broadest-in-class U.S. label in prostate cancer. Following an FDA approval in 2023 ...

Pfizer generated strong growth last year despite a significant drop in COVID revenue. The company's business is solid, and its growth prospects are encouraging. Investors, however, remain ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...

Claims on social media suggest Pfizer's COVID vaccine has fatal side effects, referencing a US House document. However, the report includes adverse events, not side effects. Adverse events ...

Pfizer appoints former J&J executive to lead obesity drug development Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

Influenza causes 140,000 to 710,000 hospitalisations and 12,000 to 52,000 deaths in the US every year, as well as economic losses of around $25 billion a year, according to Pfizer.

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

Still, almost despite itself, it points to true art. By Jason Farago and George Etheredge for The New York Times As a sprawling new exhibit opens in two museums in Amsterdam, the German artist ...